Answers are grounded in this paper and cite their sources.
Conventional approaches to managing type 2 diabetes have focused on correction of biochemical abnormalities (e.g. elevated blood glucose or lipids) or abnormal vitals (e.g. BP) and treating organ damage when it occurs (e.g. acute coronary events or diabetic eye, kidney or nerve complications), rarely addressing root causes of metabolic dysfunction. Yet, advances in understanding of cardiometabolic diseases point to excess ectopic fat as a likely common starting point, with interventions to ameliorate adiposity having the potential to prevent or delay the development of serious life-threatening complications. These shared mechanisms have inspired the concept of the speciality of ‘metabolic medicine’, encompassing elements of endocrinology, cardiology, hepatology, nephrology and neurology, as well as psychological and behavioural aspects. Availability of effective metabolic pharmacotherapies, such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose co-transporter 2 (SGLT2) inhibitors from endocrinology, as well as contemporary heart failure drugs from cardiology, renoprotective strategies from nephrology and metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)-directed therapies from gastroenterology, has further accelerated interest in this new speciality. Wider recognition of the concept of metabolic medicine has the potential to tackle the basic problem of adiposity and move away from the present glucose-centric approach of diabetologists, which could help to prevent or delay organ- and life-threatening complications.
No takes yet. Share an insight, caveat, or question.
I et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: